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ABSTRACT 
 
ERBB2-positive breast cancer is an aggressive disease form that can result in rapid tumor 
growth and metastasis driven by the overexpression of ERBB2 growth factor receptors present 
on the cell surface. Currently, approved agents can target and disable ERBB2 receptor function, 
but as few as 30% of patients with disseminated ERBB2-positive breast cancer will respond to 
these targeted therapeutics when given as single agents. Even then, many initial responders will 
soon develop resistance to these agents. Histone deacetylase inhibitors (HDACi) are a powerful 
new class of epigenetic therapeutics that have demonstrated potent antitumor activity. However, 
there are several concerns that need to be addressed regarding the clinical usage of pan-HDACi 
therapeutics, such as the standard clinical prototype hydroxamic acid, trichostatin-A (TSA). 
These include the many genomic and non-genomic targets of pan-HDACi, the off-target side 
effects, and the lack of proven HDAC-dependent cancer pathways predictive of tumor 
responsiveness. Early observations in our laboratory have shown that in vitro TSA treatment of 
breast cancer cell line models promotes accelerated decay of polyribosomally associated ERBB2 
mRNA, calling attention to a previously unrecognized transcript decay mechanism that could be 
exploited to develop new cancer therapeutics. Further studies have found that U-rich sequences 
in the 3’untranslated region (UTR) of ERBB2 transcripts are an important component of this 
transcript decay pathway. Based on these observations, we hypothesize that polyribosomally 
associated proteins, subject to regulation by HDAC-modulated protein acetylation, bind to the 
3’UTR of ERBB2 mRNA within hours of TSA treatment, and mediate its rapid degradation. 
Using the ERBB2-overexpressing human breast cancer cell line SKBR3 and an ERBB2 3’UTR 
mRNA construct and assay designed to precipitate protein complexes, we attempt to identify 
proteins physically associated with and potentially mediating the polysome-associated ERBB2 
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mRNA decay pathway. Progress in this effort is expected to lead to a cancer treatment strategy 
more effective and selective than the use of pan-HDACi for the treatment to of ERBB2 
overexpressing malignancies. 
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INTRODUCTION 
I. Breast Cancer Defined 
Breast cancer affects an estimated 220,000 women each year in the United States alone 
(DeSantis et al., 2011). As the second leading cause of death among women in the United States, 
current projections predict that one in eight women will be diagnosed with breast cancer in their 
lifetime (DeSantis et al., 2011). While the exact cause cannot be pinpointed, there are certain 
genetic mutations and aberrations thought to contribute to breast cancer development. Such 
aberrations can either activate oncogenes or inactivate tumor suppressor genes, causing normal 
cells to develop into cancerous cells (Heimann and Hellman, 2000). Today, the widespread use 
of screening mammograms aides in identifying breast cancer before symptoms develop and more 
widespread dissemination of metastatic disease takes place (Norman, 2005). However, breast 
cancer can develop in several different forms, each with varying phenotypic and molecular 
characteristics that determine both its clinical behavior and optimal treatment approach. 
 
Figure 1. Anatomy of the Female Breast (Winslow, 2011) 
 
The first description of breast cancer dates back between 3000-1500BC in Egyptian 
papyri that detailed observations fairly consistent with modern descriptions of breast cancer 
(Rayter and Manzi, 2008). Women affected with breast cancer may experience a variety of 
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symptoms, including retraction of nipple, atypical discharge from nipple, changes in skin texture, 
and atypical fullness or puckering of the breast (Fig. 1; Katz and Dotters, 2007). The most 
common symptom is a hard lump, usually in the upper outer corner of the breast (Katz and 
Dotters, 2007).  The strongest risk factors in developing breast cancer are gender and increasing 
age, placing older women at higher risk for breast cancer (Emaus, 2009). Other risk factors 
include high age at first birth, early menarche, late menopause, genetic predisposition, high 
estrogen levels, and high breast density (Harald, 2007).  
Breast cancer can be divided into clinical stages that are characterized by tumor size and 
extent of the body affected. Stage 0 is referred to as carcinoma in situ, where abnormal cells are 
found in the lining of a breast duct, lobules of the breast, or the nipple (Connolly et al., 2014). 
Currently, carcinomas in situ are not classified as cancerous (Connolly et al., 2014). Stage I is 
involvement of a tumor only within the breast, with the tumor’s maximum dimension smaller 
than 2cm (Fig. 2; Chalasani et al., 2010). Stage II means that the breast tumor may have limited 
spread into axillary lymph nodes but its size remains smaller than 5cm (Fig. 2; Chalasani et al., 
2010). These two stages are known as early breast cancer, which is considered highly curable 
because long-term patient survival rates are high if the tumor is completely excised and treated 
aggressively. The widespread use of screening mammography has been extremely important in 
detecting breast cancer in these early and clinically curable stages. Stage III breast cancer 
designates larger and more aggressive breast tumors that have spread to 4 or more axillary lymph 
nodes or invaded either the underlying chest wall or perforated the overlying skin (Fig. 2; 
Chalasani et al., 2010). Readily apparent physical changes in the composition and appearance of 
the breast occur by this later stage of breast cancer (Kataja and Castiglione, 2009; Koboldt et al., 
2012). By stage IV, the breast tumor has also spread to distant organs such as the liver, lungs, 
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and bones (Fig. 2; Kataja and Castiglione, 2009). 5-year survival rates dramatically decrease 
from 100% for stage I breast cancers to 20% or less for newly diagnosed stage III or IV breast 
cancers (Chalasani et al., 2010). 
 
Figure 2. Illustration of the progression of breast cancer (Winslow, 2011) 
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II. History of Breast Cancer Treatment 
Early stages of breast cancer can be locally treated using surgery to remove the cancerous 
cells (Chalasani et al., 2010). In 1757, Henri Le Dran, a French surgeon, was the first to suggest 
that surgical removal of the tumor could assist in the treatment of breast cancer, if infected 
lymph nodes were removed as well (Rayter and Mansi, 2008). In 1882, William Halsted tested 
Le Dran’s theory at Johns Hopkins Hospital in Baltimore, creating a new surgical technique 
called radical mastectomy (Bloom and Harries, 1962). Radical mastectomy removed the breast, 
axillary nodes, and chest muscles in a single procedure (Fig. 3; Bloom and Harries, 1962). 
Although this treatment was the gold standard for the next century, it failed to help patients with 
metastatic (stage IV) breast cancer (Rayter and Mansi, 2008).  
 
Figure 3. Anatomical Illustration of Radical Mastectomy (Winslow, 2011) 
 
By the end of the nineteenth century, scientific and medical advances, such as the 
introduction of anesthetics, helped the advancement of breast cancer treatment (Rayter and 
Mansi, 2008). George Beatson was the first to demonstrate that a portion of breast cancer 
patients had a form that was hormonally dependent (Beatson, 1896). In 1895, he developed an 
alternative surgical method to treat breast cancer (Beatson, 1896). He performed a bilateral 
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oophorectomy, removal of the ovary, on a woman who was diagnosed with extensive soft tissue 
recurrent breast cancer, and then continued treatment with a thyroid extract (Beatson, 1896). His 
treatment was a combination of surgery and endocrine therapy, which was successful in helping 
this patient experience remission and 4 years of life after the procedure (Beatson, 1896). His 
contribution was significant in that it demonstrated a combination of surgery and regulation of 
ovarian hormones was capable of helping inhibit the development of breast cancer cells. 
By the mid twentieth century, surgeons began to realize the limits in surgery alone as a 
viable means of curing patients of breast cancer (Rayter and Mansi, 2008). The deformities 
caused by the operations as well as the high risk of mortality made surgery an already daunting 
treatment for the disease (Rayter and Mansi, 2008). In light of Beatson’s findings, physicians 
began to further investigate hormone dependent growth and behavior of breast tumors. The 
importance of the hormonal milieu was reinforced with development of therapies including 
adrenalectomy (Huggins and Bergenstal, 1952) and hypophysectomy (Luft and Olivecrona, 
1955). In a third of patients who benefited, the mechanism responsible was speculated to be 
estrogen deprivation (Rayter and Mansi, 2008). This was confirmed with Jensen’s discovery of 
the estrogen receptor in many breast tumors (Jensen and Jacobson, 1960). Thereafter, invasive 
endocrine surgeries were superseded by the development of endocrine therapies, such as the 
estrogen antagonist tamoxifen in place of oophorectomy (Jordan, 2003). In accordance, 
aromatase inhibitors ultimately replaced adrenalectomy, and luteinizing hormone releasing 
hormone agonists replaced hypophysectomy, resulting in the management of patients with 
metastatic breast cancer by medical rather than surgical treatments (Rayter and Mansi, 2008). 
In addition to these findings, some surgeons began to experiment with radiotherapy as a 
form of treatment for breast cancer. Dr. Pfahler, a specialist in radiology in Philadelphia, used 
 6 
radiotherapy on over a thousand patients with breast cancer, including many patients that were 
too frail for surgery (Case, 1955). Patients with early forms of the disease had a 5-year survival 
rate of 80%, demonstrating the effectiveness of this local radiotherapy approach (Case, 1955). 
Dr. McWhirter of England used a combination of mastectomy with radiotherapy to the 
supraclavicular, internal mammary and axillary lymph nodes in 759 patients (McWhirter, 1949). 
The results indicated that a combination of the therapies resulted in higher 5-year survival rates 
than either treatment alone (McWhirter, 1949).  However, treatment for more aggressive forms 
of breast cancer still remained a mystery for much of the twentieth century. 
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III. ERBB2 (HER2) Positive Breast Cancer 
Research and clinical evidence over the past two decades have pointed to the fact that 
breast cancer commonly develops into one of about 3 or 4 different clinical subtypes: luminal, 
hormone receptor (ER or PR)-positive; basal-like (often referred to as triple-negative because it 
lacks expression of ER, PR and ERBB2); and ERBB2 (also commonly called HER2)-positive 
breast cancers (Chaudhury et al., 2010). ERBB2-positive breast cancer makes up 20-25% of all 
breast cancer cases (Dent et al., 2013). ERBB2 is a member of the epidermal growth factor 
receptor (EGFR) family of receptor tyrosine kinases, and the overexpression of this cell surface 
growth factor receptor plays an important role in the pathogenesis of breast cancer (Fang et al., 
2014). A non-malignant mammary epithelial cell expresses about 20,000 ERBB2 receptors, 
while an ERBB2-positive breast cancer cell may express 100 times the normal number of 
receptors on the cell surface due to the amplification of the ErbB2 oncogene (King et al., 1985; 
Kumar and Badve, 2008; Turner and Leo, 2013). This gene amplification and overexpression of 
ERBB2-encoded mRNA and protein occurs early during the tumorigenic process and leads to 
rapid growth and division of the transformed epithelial cells and also confers other malignant 
characteristics including cell motility and invasiveness that facilitates metastatic dissemination 
(Moasser, 2007; Koboldt et al., 2012).  Thus, women with the ERBB2-positive subtype of breast 
cancer are 11 times more likely to die from their disease (Chalasani et al., 2010). 
Four tests have been developed to detect ERBB2-positive breast cancers and to 
distinguish this subtype from other breast cancer subtypes. The most common is 
immunohistochemistry (IHC), which measures ERBB2 protein expression on a 0 to 3+ scale: 0-
1+ is negative, 2+ is borderline, and 3+ is ERBB2 positive (Ely and Vioral, 2007). Another 
common test is fluorescence in situ hybridization (FISH). This method assesses the degree of 
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ERBB2 gene amplification found in individual cancer cells, and results are indicated as positive 
or negative based on the presence of gene amplification (Ely and Vioral, 2007). A positive FISH 
test signifies the presence of at least double the normal level of the oncogene in each breast 
cancer cell (Kataja and Castiglione, 2009). Less common tests include the SPoT-Light ErbB2 
CISH test and Inform ErbB2 Dual ISH test, which are similar to FISH in assessment of ERBB2 
amplification as well as reporting a tumor as being either ERBB2/HER2 positive or negative 
(Ely and Vioral, 2007). It is important to note that while these tests are used to designate a tumor 
as ERBB2-positive and thereby identify the breast cancer patient as eligible to receive an anti-
ERBB2 therapeutic, none of them can identify exactly which patients will benefit from that 
targeted therapeutic agent (Emaus, 2009; Harald, 2007). Not only are newer and more effective 
anti-ERBB2 therapies needed, but also needed are newer biomarkers predicting the clinical 
benefit (or not) of different ERBB2-targeted agents.   
 
  
 IV. Treatment for ERBB2 (
The first form of treatment for
antibody, mumAb4D5, which bound specifically and tightly
ERBB2 receptor (Fig. 4A; Carter 
growth of breast tumor-derived cells line as well as facilitate immune attack against
positive cancer cells (Slamon et 
named trastuzumab, and marketed by Genentech as Herceptin
clinical trials before finally being approved by the FDA in 1998 
Many patients experienced an increase in quality and length of their lives
trastuzumab; however, a significant percent of patients with ERBB2
did not respond to this antibody or developed resistance to 
Figure 4. Various treatments for ERBB2
interference with the extracellular domain of the ERBB2 receptor. B) Lapatinib interference with the intracellular 
domain of ERBB2 monomers and dimers
Neratinib interference with the intracellular domain of ERBB2 receptors.
 
HER2) Positive Breast Cancer 
 ERBB2-positive breast cancers was a monoclonal 
 to the extracellular domain of the 
et al., 1992). MumAb4D5 was shown to specifically inhibit the 
al., 1987). The humanized form of that murine
; it went through a long process of 
(Kumar and Badve, 2008)
 
-positive breast cancer either 
it within a year (Jackisch, 2008)
-positive breast cancer and their mechanism of action.  A) Trastuzumab 
. C) Pertuzumab inhibition of the dimerization of E
 (Park et al., 2011) 
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To address clinical resistance to trastuzumab, Genentech developed another monoclonal 
antibody called pertuzumab (Jackisch, 2008). It targets another epitope on the extracellular 
domain of ERBB2 receptors to specifically inhibit the dimerization of ERBB2 receptors, 
resulting in a more comprehensive blockade of ERBB2 signaling (Fig. 4C; Park et al., 2011). 
Low molecular weight compounds have also been developed to inhibit the receptor’s 
intracellular ATP binding site and thereby prevent its downstream signaling; two such agents 
include Lapatinib and Neratinib (Fig. 4B and 4D; Park et al., 2011). Even with the variety of 
treatments now available to disable the ERBB2 receptor function needed for the cancer cell’s 
growth and metastatic spread, as few as 30% of patients with ERBB2-positive breast cancer 
respond clinically to these drugs and many others later develop clinical resistance after initial 
clinical response (Kute et al., 2004).  
A common feature of all the above anti-ERBB2 therapeutics developed to date is that 
they directly target the surface receptor protein, not any of the key signaling and downstream 
tumorigenic pathways driven by overexpressed ERBB2. A novel mechanistic point of attack for 
the development of a newer anti-ERBB2 therapeutic would be to target the overexpressed 
ERBB2 mRNA that is translated into ERBB2 receptor protein—not simply inhibiting function of 
the already encoded protein—but accelerating the cytoplasmic decay of the normally long-lived 
and abundant ERBB2 mRNA produced off the amplified ERBB2 gene. Initial insight into the 
feasibility of such a novel mechanistic point of attack came from our studies of histone 
deacetylase (HDAC) inhibitors in ERBB2-positive breast cancer cell line models. 
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V. HDACi as a New Therapeutic Tool 
In general, the dysregulation of gene expression and function leads to a combination of 
genetic and epigenetic abnormalities that influence the development of breast cancer (Jones and 
Baylin, 2007). A very common epigenetic abnormality during tumor development is the altered 
expression of histone deacetylases (HDACs) (Ellis et al., 2009). HDACs are enzymes that 
regulate gene transcription and expression by removing ε-N-acetyl lysine residues off histone 
tails of chromatin and by the deacetylation of non-histone proteins (Fig. 5; Bolden et al., 2006). 
The basic mechanism of acetylating histones via histone acetyl transferases (HATs) removes the 
positive charge of the histones, which decreases its interaction with the negative phosphate 
groups of DNA. This in effect relaxes the chromatin structure to allow for transcription. 
However, HDACs oppose this activity and help maintain the closed structure of chromatin. To 
influence gene transcription in normal tissue and cancerous cell lines, HDACs do not directly 
bind DNA; instead, they require interaction with other proteins associated with large multi-
protein complexes (Choudhary et al., 2009). Various studies have demonstrated the aberrant 
expression of HDACs during tumorigenesis as well as progression to metastatic phenotypes 
(Ellis et al., 2009; Glozak and Seto, 2007; Nakagawa et al., 2007; Scott et al., 2002). 
 
Figure 5. Schematic representation of HAT, HDAC, and HDACi mechanism of action. (Todd et al., 2012) 
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18 HDACs have been identified in humans and are classified into four groups (I, II, III, 
and IV) based on structural differences (Fig. 6; Glozak and Seto, 2007; Chun, 2015; 
Dokmanovic et al., 2007). Classes I, II, and IV require Zn2+ as a cofactor; however, class III 
HDACs are sirtuins that are Zn2+ independent, and will not be considered here (deRuijter et al., 
2003; Gregoretti et al., 2004). Class I HDACs have a single catalytic site and are localized in the 
nucleus, whereas class II HDACs are found in both the nucleus and cytoplasm, containing zinc 
in their 1-2 catalytic sites (Dokmanovic et al., 2007). Knockout analyses of different class I and 
class II HDAC proteins indicate that class I HDACs play a role in cell survival and proliferation, 
while class II HDACs may have tissue-specific roles (Minucci and Pelicci, 2006). HDAC4, 
HDAC6 and HDAC11 were specifically shown to be overexpressed in breast cancer tissue 
(Nakagawa et al., 2007; Scott et al., 2002). 
 
Figure 6. HDACs, their classifications, targets, and downstream signaling results as well as anticancer outcomes of 
HDAC inhibition. Class I HDACs (1-3 and 8) target histone substrates in addition to transcription factors like p53. 
Class II HDACs (4-11) target non-histone substrates such as SMC3 (structural maintenance of chromosomes 3), 
HP1 (heterochromatin protein 1), and tubulin resulting in dysregulated cell signaling and altered transcription 
activity. Implementation of HDACi results in apoptosis, senescence, cell cycle arrest, and other antitumor responses 
as highlighted in the lowermost portion of the diagram. (West and Johnstone, 2014) 
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Histone deacetylase inhibitors (HDACi) are a powerful new class of epigenetic 
therapeutics for the treatment of various malignancies such as breast cancer. Normal cells are 
relatively resistant to HDACi induced cell death; however, malignant cells have been shown to 
respond well with HDACi treatment (Milos et al., 2007). The most commonly used and earliest 
forms of HDACi include sodium butyrate, valproate, vorinostat, MS-275, romidepsin and 
trichostatin-A (Glozak and Seto, 2007). HDACi treatment results in increased histone 
acetylation, producing transcriptional activation of critical genes needed for tumor growth arrest 
(Glozak and Seto, 2007). The therapeutic value of HDACi comes from findings that normal cells 
are relatively resistant to HDAC inhibitor-induced cell death compared to tumor cells 
(Ungerstedt et al., 2005). HDAC inhibitors are also known to modify a number of tumor related, 
non-histone proteins in their pathway, producing an increase in acetylation that is associated with 
several molecular processes including the inhibition of angiogenesis and the induction of 
autophagy and apoptosis (Ellis et al., 2009).  
HDACi can be categorized as either pan-HDACi, which target all HDACs, or class-
selective HDACi, which target specific classes of HDACs. The difference lies in HDACi 
potency, isoform selectivity, and efficacy against various diseases (Berkley et al., 2012). In 
general, pan-HDACi are more potent, but class-selective HDACi may trade potency for greater 
selectivity, less toxicity and hence improved therapeutic index. However, with the many 
genomic and non-genomic targets of pan-HDACi independent of the specific transcript’s 
function, the off-target side effects of pan-HDACi and the lack of other proven HDAC-
dependent cancer pathways predictive of tumor responsiveness have been major concerns that 
have slowed the non-hematologic clinical development of pan-HDACi against solid tumors like 
breast cancer.  
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VI. Current HDACi Research  
Previous findings in our laboratory have demonstrated that 6-hour pan-HDACi treatment 
(trichostatin-A or TSA) induces ERBB2 mRNA decay (Fig. 7 and 8A; Scott et al., 2002). Early 
observations in our laboratory (using TSA) not only inhibits ERBB2 transcription by promoter 
repression, but also induces ERBB2 protein destabilization and accelerated decay of ERBB2 
transcripts (Fig. 7 and 8; Scott et al., 2002).  Polysome profiling, normalized using GAPDH, 
revealed that ERBB2 transcripts are concentrated in fractions 17-23, which are polyribosomally 
associated (Fig. 8B and 8C). A 2-3 fold decrease in ERBB2 mRNA is observed in the same 
fractions when exposed to 6-hour treatment of TSA (Fig. 8C and 8D).   
 
Figure 7.  SKBR3 human breast cancer cells probed with Stellaris FISH probes to ERBB2/HER2 mRNAs show 
decrease in HER2 mRNA levels. A) Hundreds of cytoplasmic HER2 mRNA transcripts found in untreated breast 
cancer cells, with multiple bright spots of active transcription within the nuclei. B) HER2 transcript levels are 
markedly reduced with the addition of the HDACi TSA (trichostatin-A) as evidenced by the disappearance of both 
cytoplasmic and bright nuclear spots. (Orjalo et al., 2011) 
 
 
  
 Figure 8. HDACi induced ERBB2 mRNA decay initiates on the polyribosome. A) Northern Blot analysis 
demonstrating 6-hour TSA treatment on SKBR3 cells results in 
GAPDH transcripts. B) Sucrose gradient (15%
cytosolic lysates into free cytosol (#1-5), 40S, 60S and 80S m
subsequent Northern and Western Blotting.
treated SKBR3 sucrose gradient fractions probed with ERBB2 and GAPDH relative to ethidium stained 
showing 28S, 18S, and t-RNA bands. Reduced ERBB2/GAPDH 
that HDACi induced ERBB2 mRNA decay originates on polysomes; no 
detected in the free cytosol fractions.
levels of ERBB2 transcripts under control and 6 hour TSA treatment conditions 
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ERBB2 signaling activates the PI3K/Akt/mTOR pathway, which promotes cell survival 
and division, by inducing the phosphorylation of the 40s ribosomal subunit protein S6 (RPS6) 
and the eukaryotic initiation factor 4e binding protein 1 (4eBP1) (Wilson-Edell et Al, 2014). 
These events have been shown to stimulate polyribosome assembly and increase translation of 
tumorigenic mRNAs (Thoreen et al., 2012). Preliminary findings by our laboratory show that 
ERBB2 is associated with the polyribosome and that TSA induced decay of ERBB2 mRNA also 
primarily occurs at the polyribosome.  
Since the mechanism responsible for ERBB2 mRNA decay is unknown, these findings 
led us to question the proteins involved in the ERBB2 mRNA decay pathway, specifically ones 
that are polyribosomally associated. Further studies have found that U-rich sequences in the 
3’untranslated region (UTR) of ERBB2 transcripts are an important component of the decay 
pathway, since specific proteins are known to bind to the 3’UTR and modulate transcript 
stability (Abdelmohsen, 2012; Scott et al., 2007). Based on these observations, we hypothesize 
that polyribosomally associated proteins, subject to regulation by HDAC-modulated protein 
acetylation, bind to the 3’UTR of ERBB2 mRNA within hours of TSA treatment and mediate its 
rapid degradation. Using the ERBB2-overexpressing human breast cancer cell line SKBR3 and 
an ERBB2 3’UTR mRNA construct to bind and precipitate protein complexes, we attempt to 
identify proteins physically associated with and potentially mediating the polysome-associated 
ERBB2 mRNA decay pathway. 
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MATERIALS AND METHODS 
 
 Culture Growth, Treatment, and Harvesting of Human Breast Cancer Cell Line 
The ERBB2-positive human breast cancer cell line, SKBR3, was obtained from 
American Type Culture Collection and used in this study. The cells were grown in McCoy’s 
medium (Cellgro, Manassas, VA) supplemented with 10% fetal bovine serum and 1% 
penicillin/streptomycin. Experimental cells were treated with commercially obtained (Sigma-
Aldrich, St. Louis, MO) trichostatin-A (TSA) for 2, 4, or 6 hour time periods at a concentration 
of 1.5 µM. This specific concentration allows for a dynamic change in cellular activity without 
killing the cell. Various time points were chosen to allow for detection of differential binding of 
polyribosomal protein, with 6 hours being the maximum before cell death is induced. 
Control and treated cells were harvested and dounced in a hypotonic buffer containing 50 
mmol/L of Hepes (pH 7.4), 10 mmol/L of KCl, 0.3% NP40, 10 mmol/L of MgCl2, 100 Units/mL 
of SUPERasein (Ambion, Grand Island, NY), and mini-complete protease inhibitors (Roche 
Diagnostics, Nutley, NJ). The cell lysate was then centrifuged at 16,000 rpm for 5 minutes to 
remove nuclei and other insoluble material. Cytosolic extracts were incubated with 1 to 2 mg/mL 
of poly[d(I-C) in 100 mmol/L of KCl, 10 mmol/L of Tris-HCl (pH 7.5), 2 mmol/L of DTT, and 
20% vol/vol glycerol at 23C. 
 Polysome Profiling 
Polysome profile analysis was employed on whole cell lysates collected as described 
above. The lysates were layered on top of a 10%-50% continuous sucrose gradient (Fig. 9). The 
samples were then spun at 38,000 rpm for 2 hours at 4 C. The gradients were fractioned, and 
 polysome fractions were then collected 
(UA6). 
Figure 9. Schematic representation of poly
polysome-profiling graph created by the 
 
 ERBB2 3’UTR mRNA Construct
EST clones containing 3’UTR sequence of ERBB2 were commercially obtained 
(Invitrogen, Grand Island, NY) and cloned into the XbaI site of the pBluescript KS(
(Fig. 10; Stratagene, Santa Clara, CA
for the transcript to be inserted in both the forward and reverse
probability—forward being the sense strand and reverse being the antisense strand. 
was linearized using a HaeIII digest (Sigma Aldrich, St. Louis, MO).
contains an internal BstXI site at 170 bp in addition to the BstXI site12 bp upstream of the XbaI 
site in the vector; thus, after the restriction enzyme disgest, the segment that is 183bp is in the 
sense strand orientation and the 430bp
RNA polymerase T7 used digoxigenin
using the Retriever 500 with ISCO Teledyne UV/Vis 
 
some profiling from formation of continuous sucrose gradient to the 
ICO Teledyne UV/Vis. (Abdelmohsen, 2012) 
 and Digoxigenin Labeling 
). Blunt ends were used when inserting the 3’UTR to a
 orientation with equal 
 The 3’UTR of E
 segment produced is in the antisense orientation. 
-labeled UTP as a ribonucleoside at a 1:15 ratio (~10 U’s 
18 
-) vector 
llow 
The vector 
RBB2 
The 
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in 3’UTR of ErbB2). The labeled mRNA was then purified by Nuc Spin columns (Ambion, 
Grand Island, NY) to remove any unincorporated digoxigenin. Reaction products were 
electrophoretically separated on an 1.5% formaldehyde-agarose gel (0.9g of agarose, 6mL of 
10X MOPS, 43mL of ddH2O, and 11mL of formaldehyde), and bands were visualized by 
autoradiography to confirm orientation. RNA was subsequently denatured by a 5-minute 
incubation at 65 C. 
 
Figure 10. Schematic representation of ERBB2 3’UTR insertion into pBluescript KS(-) vector for polymerase T7 
transcription using digoxigenin-labeled UTP as a ribonucleoside.  
 
 RNA Immunoprecipitation 
Denatured RNA probe was combined with different SKBR3 cytoplasmic extracts: control 
extract from untreated cells and HDACi-treated extracts from cells treated with trichostatin A 
(TSA) for 2, 4, or 6 hours. Cells were first heat shocked for 5 min at 37 C and then cooled at 
room temp for 15 min. 0.2 µg of sheep anti-digoxigenin antibody and 12 µL of protein G 
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sepharose beads (GE Healthcare, Pittsburg, PA) per milliliter of lysate were added to 
cytoplasmic extracts with RNA, which were then rotated for 1.5 hours. The protein G beads from 
the were washed once at 4C in wash buffer (composed of 20 mmol/L of Tris (pH 7.4), 50 
mmol/L of KCl, 10 mmol/L of MgCl2, and 0.3% NP40), resuspended in 1X loading buffer [20 
mmol/L of Tris (pH 6.9), 2% SDS, 1% 2-mercaptoethanol, 50 mmol/L of NaCl, and 10% 
glycerol], heated to 95 C for 10 min, and stored in a -80 C freezer (Fig. 11). 
 
 
Figure 11. Schematic representation of immunoprecipitation reaction pulling down digoxigenin-labeled 3’UTR of 
ERBB2 mRNA protein probe bound with complexes using Protein G beads coated in anti-digoxigenin antibody. 
 
 
 Western Blotting 
Equal aliquots of immunoprecipitated material were electrophoresed using NuPAGE 4% 
gradient polyacrylamide gel (Invitrogen, Grand Island, NY) in 10% MES buffer for 30 minutes, 
transferred at 200V to nitrocellulose (Amersham Bioscience, Pittsburgh, PA) and probed with 
various antibodies (see below) in hybridization buffer (20 mmol/L of Tris (pH 7.5), 130 mmol/L 
of NaCl, and 0.05% Tween 20) with 5% nonfat milk. Hybridized antibodies were visualized 
using chemiluminescence, since antibodies used are labeled with chemiluminescent substrate 
horseradish peroxidase (HRP). Blots were treated with SuperSignal® West Pico Stable Peroxide 
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Solution and West Pico Luminol/ Enchancer solution (Cell Signaling, Beverly, MA) at a 1:1 
ratio to visualize results on chemiluminescent film. The antibodies tested included HuR (mouse 
3A2; Santa Cruz Biotechnology, Santa Cruz, CA), RNH1 (mouse H-135; Santa Cruz 
Biotechnology, Santa Cruz, CA), CyPA (rabbit C-14; Santa Cruz Biotechnology, Santa Cruz, 
CA), hnRNP K (rabbit A300-675A; Bethyl Labs, Montgomery, TX), p68 (rabbit H-144; Santa 
Cruz Biotechnology, Santa Cruz, CA), and RACK1 (mouse B-3; Santa Cruz Biotechnology, 
Santa Cruz, CA). 
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RESULTS 
I. Identification of Differential Protein Binding to 3’UTR of ERBB2 mRNA  
In order to identify protein associated with the 3’UTR of ERBB2 mRNA, we created an 
assay where a 3’UTR construct of ERBB2 mRNA (see Material and Methods) was placed in a 
whole cell lysate to immunoprecipitate associated protein complexes. The immunoprecipitation 
reaction consisted of a control cytosolic lysate and a 2-hour TSA-treated cytosolic lysate, and 
both lysates were combined with the digoxigenin-labeled 3’UTR construct of ERBB2 mRNA in 
both the sense and antisense orientations. The reaction pulled down digoxigenin labeled mRNA 
and any bound protein complexes with it. Products of the immunoprecipitation reactions (sense 
untreated, sense 2-hour TSA treated, antisense untreated, and antisense 2-hour TSA treated) were 
loaded in the first four lanes of a polyacrylamide gel. Total cell lysate that was untreated as well 
as treated with TSA for 2 hours was loaded in the last two lanes as indication of total protein 
present. The resultant gel, stained with SyphroRuby (Invitrogen, Grand Island, NY), revealed a 
multitude of protein bands in both sense and antisense stands as well as in treated and non-
treated lanes (Fig. 12). The lysate lanes show a difference in total protein acetylation with 2 hour 
TSA treatment. However, visual inspection could not discriminate protein bands with differential 
intensity in the treated and non-treated lanes that were also specifically bound to the sense strand. 
Due to this lack of sensitive resolution, specific bands were excised from the gel (Fig. 12, red 
boxes) and analyzed by mass spectrometry. 
  
Figure 12. SyphroRuby stained gel reveals abundance of protein binding to 3’UTR of ERBB2 mRNA 
of resolution to determine specific protein bands with high specificity to the sense strand versus the antisense strand. 
Red boxes indicate sections of the gel excised and analyzed by mass spectrometry to identify strand specific protein 
binding, while blue boxes indicate light chain and heavy chain interaction of the antibody used in the 
immunoprecipitation reaction. 
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but with lack 
 24 
Only segments of the control sense and control antisense lanes were analyzed by mass 
spectrometry to help identify proteins with sense (coding) strand binding specificity to the 
3’UTR of ERBB2 mRNA. Mass spectrometry identified several proteins bound to the 3’UTR of 
ERBB2 in both a sense strand-specific and non-strand specific manner (Appendix 2). In order to 
distinguish protein candidates for further analysis, we looked for proteins that showed at least a 
two-fold preferential binding to the sense strand using a sense to antisense strand ratio. Of the 
502 proteins that were identified by mass spectrometry, only 42 protein candidates met this 
criterion (Appendix 1). Several of these proteins were heterogeneous nuclear ribonucleoproteins 
(hnRNP), which are complexes of RNA and protein present in the cell nucleus during gene 
transcription and subsequent transcriptional modification of pre-mRNA (Chaudhury et al., 2010; 
Table 1). Most of these hnRNPs showed a two-fold difference in specificity to the sense strand 
versus the antisense strand. 
Table 1: Heteronuclear Proteins Discovered from MS Analysis 
Protein  Gene  Name  Ratio 
(sense/antisense) 
ELAV1  ELAVL1  ELAV-like protein 1 (HuR) [CONTROL] 2.1 
ROAA  HNRNPAB  Heterogeneous nuclear ribonucleoprotein A/B  >1 
ROA1  HNRNPA1  Heterogeneous nuclear ribonucleoprotein A1  2.8 
RA1L2  HNRNPA1L2  Heterogeneous nuclear ribonucleoprotein A1-like 2  2.8 
ROA3  HNRNPA3  Heterogeneous nuclear ribonucleoprotein A3  2.9 
HNRCL  HNRNPCL1  Heterogeneous nuclear ribonucleoprotein C-like 1  1.9 
HNRPD  HNRNPD  Heterogeneous nuclear ribonucleoprotein D0  3 
HNRDL  HNRNPDL  Heterogeneous nuclear ribonucleoprotein D-like  3 
HNRPF  HNRNPF  Heterogeneous nuclear ribonucleoprotein F  1.2 
HNRH1  HNRNPH1  Heterogeneous nuclear ribonucleoprotein H  2.2 
HNRH3  HNRNPH3  Heterogeneous nuclear ribonucleoprotein H3  1 
ROA2  HNRNPA2B1  Heterogeneous nuclear ribonucleoproteins A2/B1  4 
HNRPC  HNRNPC  Heterogeneous nuclear ribonucleoproteins C1/C2  1.9 
HNRPU  HNRNPU  Heterogeneous nuclear ribonucleoprotein U  3.8 
HNRPK  HNRNPK  Heterogeneous nuclear ribonucleoprotein K  2.7 
HNRL1  HNRNPUL1  Heterogeneous nuclear ribonucleoprotein U-like protein 1  13.4 
  
  
 25 
There were also a few strong candidates, other than hnRNP’s, present in multiple 
isoforms and that had strong sense-strand specificity as identified by mass spectrometry (Table 
2). The strongest non-hnRNP candidate was peptidylprolyl isomerase A (PPIA), which catalyzes 
the cis-trans isomerization of proline imidic peptide bonds in oligopeptides and accelerates the 
folding of proteins (Pliyev and Gurvits, 1999). PPIA demonstrated a 42.7times stronger 
specificity to the sense strand over the antisense strand, on average of the various isoforms 
detected. The other non-hnRNP candidates were probable ATP-dependent RNA helicases, 
specifically DEAD box proteins characterized by the conserved motif Asp-Glu-Ala-Asp (DEAD) 
(Andreou and Lkostermeier, 2014). They are responsible for catalyzing the ATP-dependent 
unwinding of RNA duplexes and accompany RNA molecules throughout their cellular life 
(Andreou and Lkostermeier, 2014). Mass spectrometry analysis demonstrated, on average of the 
various isoforms detected, a 4.7 fold difference in specificity to the sense strand over the 
antisense strand (Table 2). 
 
Table 2: Non-hnRNP Protein Candidates from MS Analysis (Present in Multiple Isoforms) 
Precursor 
(molecular weight) 
Protein Ratio 
(sense/antisense) 
Average 
Ratio 
528.27 Peptidyl-prolyl cis-trans isomerase A            27.5         42.7 
577.79 Peptidyl-prolyl cis-trans isomerase A            47.9 
624.32 Peptidyl-prolyl cis-trans isomerase A            58.9 
684.87 Probable ATP-dependent RNA helicase DDX5            11.1         4.7 
547.78 Probable ATP-dependent RNA helicase DDX5            6.4 
648.33 Probable ATP-dependent RNA helicase DDX5            3.4 
468.77 Probable ATP-dependent RNA helicase DDX5            2.5 
613.86 Probable ATP-dependent RNA helicase DDX5            4.2 
565.33 Probable ATP-dependent RNA helicase DDX5            9.9 
492.76 Probable ATP-dependent RNA helicase DDX5            2.2 
493.29 Probable ATP-dependent RNA helicase DDX5            4.1 
426.72 ATP-dependent RNA helicase DDX3X            2.1         2.6 
547.28 ATP-dependent RNA helicase DDX3X            2.1 
582.30 ATP-dependent RNA helicase DDX3X            1.3 
434.22 ATP-dependent RNA helicase DDX3X            6.4 
584.86 ATP-dependent RNA helicase DDX3X            3.3 
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II. Establishing Sense-Strand Specificity with HuR as a Positive Control  
 
Previous data from our laboratory established ERBB2 expression is regulated by the 
transcript stability factor HuR (Human Antigen R) (Scott et al., 2008). An in vitro binding assay 
demonstrated that HuR is capable of binding to a radiolabelled probe consisting of the conserved 
U-rich element of the ERBB2 3’UTR mRNA, established by the supershift induced in the HuR-
probe complex (Fig. 13B). In addition, polysome fractions used in earlier experiments to 
demonstrate decaying levels of ERBB2 mRNA upon TSA treatment were probed with HuR to 
confirm that HuR was polyribosomally associated (Fig. 13D). As mentioned earlier, ERRB2 
decay was shown to initiate on the polyribosome; therefore, we are searching for protein 
candidates that could also associate with the polyribosome. Western blot analysis revealed that 
high concentrations of HuR are found in the cytosol and notable amounts were found to be 
associated with the polyribosomal fractions (Fig. 13E). 
Results from mass spectrometry showed that HuR, also known as ELAV1, binds with a 
2-fold higher specificity to the sense strand in comparison to the antisense strand (Table 1). We 
used Western blot analysis to confirm that stability factors bind with greater affinity to the 
coding strand of ERBB2 mRNA. As shown in Figure 13C, HuR bound to the sense strand in 
both untreated and treated immunoprecipitates, but not to the antisense strand in the untreated 
and treated immunnoprecipitates (Fig.13C). Due to the stable and non-differential expression of 
HuR in both the treated and non-treated lanes, it serves as a positive control for the rest of the 
immunoprecipitate data. 
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Figure 13. ERBB2 expression is regulated by the transcript stability factor, HuR, which binds a conserved U-rich 
element in the sense strand of the 3’ UTR of ERBB2 mRNA. A) Western Blot analysis, using immunoprecipitates 
with sense vs. antisense 3’UTR ERBB2 mRNA constructs, reveals that HuR specifically binds to the sense strand of 
the 3’UTR of ERBB2. B) 6-hour TSA-treated SKBR3 cell fractions demonstrating expression of ERBB2 mRNA in 
fractions associated with the polysome. Same treated fractions in are probed with HuR on a Western Blot and shown 
at the bottom. High concentrations are found in the cytosol and notable amounts are found in the polysomally-
associated fractions.  
  
 III. Western Blot Analysis of Protein Candidates Identified b
 
Peptidylprolyl isomerase A (PPIA), also known as cyclophilin A, was the strongest 
protein candidate identified by mass spectrometry 
strand (Table 2). Studies have demonstrated its overexpression in several cancers, including 
breast cancer (Hathout et al., 2002; Zheng 
not confirm sense-strand specificity
regardless of treatment (Fig. 14). 
the cytoplasmic lysates but not the immunoprecipitates containing t
(Fig. 14A). Polysome profiling analysis also revealed that 
polyribosome (Fig. 14B). 
 
 
Figure 14. Western blot analysis does not confirm mass spectrometry results for PPIA. A) Western blot 
using the CyPA antibody shows that PPIA is 
treated immunoprecipitates. B) Western blot 
comparison to HuR, with the last notable signal ending in fra
 
 
Probable ATP-dependent RNA helicase DDX5
protein candidate identified by mass spectrometry with 
(Table 2). Studies have identified DDX5 as a required factor fo
y Mass Spectrometry 
showing the greatest affinity to the sense 
et al., 2008). However, Western blot analysis could 
 as seen by the lack of PPIA in the sense and antisense 
Furthermore, Western blot analysis only recognized PPIA in 
he ERBB2 mRNA construct 
PPIA is not associated 
 
absence in both sense or antisense strands for control and 2
analysis shows that PPIA is not polyribosomally associated in 
ction 7 for PPIA. 
, also known as p68, was another strong 
a higher affinity to the sense strand 
r cell proliferation in certain 
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with the 
analysis 
-hour TSA-
 breast cancer cells (Mazurek et al., 2012)
3’UTR of ERBB2 mRNA but specificity for the sense strand over the antisense
confirmed (Fig. 15A). The non-treated 
intensity, with greater binding to the sense strand; however, the same difference in intensity was 
not noted in the treated sense and antisense lanes. Looking at polysome profile analysis, DDX5 
did show to be closer to the polyribosomal fractions than PPIA; however, there is a significant 
drop off in signal after fraction 9 (Fig. 15
 
 
Figure 15. Western blot analysis partially confirms mass spectrometry results for DDX5
using the p68 antibody shows that DDX5 is present in both sense 
treated immunoprecipitates. B) Western blot 
comparison to HuR, with the last notable signal ending in fraction 9.
 
 
  
. Western blot analysis identified DDX5 binding to the 
 could not be 
sense and antisense strands did show a difference in 
B). 
. A) Western blot 
and antisense strands for control and 2
analysis shows that DDX5 may be polyribosomally associate
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analysis 
-hour TSA-
d in 
 Another weaker candidate, ribonuclease inhibitor 1 (RNH1), was tested using 
blot analysis due to its role in HDACi resistance in certain cancers and its role in mRNA 
turnover (Zhu et al., 2014). RNH1 was detecte
preferential binding to the sense strand. 
Western blots due to it strong association with the polysome and absence in cytoplasmic 
fractions (Wilson-Edell, 2014). However, like PPIA, no signal could be detected in sense and 
antisense lanes of the immunoprecipitates of both control a
We briefly looked at possible differential expression resultant of TSA treatment in po
fractions since we were unable to investigate this in our pulldown. However, p
analysis confirmed that RNH1 is not associated 
cytosolic fractions (Fig. 16B). 
 
 
Figure 16. Western blot analysis confirms that RNH
pathway. A) Western blot analysis shows that RNH1 is not present in 
2-hour TSA-treated immunoprecipitates. B) Western blot 
associated in comparison to RACK1, with the last notable signal ending in fraction 6 of the treated fractions.
 
 
  
d in our mass spectrometry analysis with a 1.8 fold 
RACK1 is used to normalize for loading error in further 
nd 2-hour TSA treatment (Fig. 16
olysome profile 
with the polyribosome and is mainly pres
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IV.  hnRNP K as a Strong Candidate Mediating ERBB2 mRNA Stability  
Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is an essential RNA- and DNA-
binding protein involved in gene expression and signal transduction including DNA 
transcription, RNA splicing, RNA stability, and translation (Zhou et al., 2010). Several studies 
have shown overexpression of hnRNP K in breast cancer and its importance in tumor cell 
viability (Van Domselaar et al., 2012; Zhou et al., 2010). Mass spectrometry identified hnRNP K 
with a three-fold difference in its specificity to the sense strand over the antisense strand (Table 
1). Western blot analysis showed hnRNP K was present in both sense and antisense strands for 
control and 2-hour TSA-treated immunoprecipitates (Fig. 17A). However, there was a notable 
difference in intensity when comparing the sense strand of the control to that of the 2-hour TSA-
treated lane. This was further investigated in Western blot analysis of polysome fractions (Fig. 
17B). The results demonstrated that in addition to hnRNP K being polyribosomally associated, it 
bound 3-times more strongly to TSA-treated fractions than control fractions (Fig. 17B). These 
findings indicate that hnRNP K is a strong protein candidate mediating ERBB2 mRNA decay. 
 
 
  
Figure 17. Western blot analysis reveals hnRNP K as a strong protein candidate that shows differential binding to 
the 3’UTR of ERBB2 mRNA following TSA treatment and is polyribosomally associated. A) Western blot 
shows hnRNP K is present in both sense and antisense s
immunoprecipitates. However, a notable difference in intensity in the sense strand of the control and treated lanes 
suggests that hnRNP K is involved in ERBB2 degradation following HDACi treatm
polysome fractions demonstrates hnRNP K is polyribosomally associated, shows 
fractions in comparison to control fractions
 
 
 Based on this data, we wa
extended polysome fractions to confirm its ribosomal association and differential expression 
with TSA treatment. When comparing later polysome fractions (16+), there is a noticable 
difference in the expression levels of hnRNP K in the control and 2
(Fig. 18). In the absence of treatment
polyribosomal fractions; however, in the presence of 2
expression sustains itself to later polyribosomal
charting the expression levels, the difference in expression levels between the control and treated 
fractions are similar in early fractions, but after fraction 1
significantly different (Fig. 18 B and D). 
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3 times greater binding to treated 
 as indicated by quantified expression levels below the blot
nted to further investigate expression patterns of hnRNP K in 
-hour TSA-treated fractions
, hnRNP K expression drops rapidly before the 
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Figure 18. 2-hour TSA treatment induces stronger hnRNP K expression in polyribosomally associated fractions. A) 
Single Western blot analysis reveals relative expression of hnRNP K is similar in earlier monosomal fractions 
regardless of treatment, but a 2 fold or greater expression is indicated in fractions treated with TSA that are 
polyribosomally associated. B) Graphic analysis of data in part A uses hnRNPK/RACK1 expression ratio on the y-
axis to visualize the significant difference of hnRNP K expression in fractions 21 and 23 following 2-hour treatment 
with TSA. C) Extended Western blot analysis using later fractions measures the extent of hnRNP K in later 
polyribosomal fractions. D) Graphic analysis of data in part C visualizes the stark drop-off of hnRNP K expression 
in control fractions after 16, whereas 2-hour TSA-treated fractions sustain expression until fraction 34.   
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DISCUSSION 
We were able to identify differentially bound polyribosomal proteins to the coding-strand 
sequence of the 3’UTR of ERBB2 mRNA, which helped uncover some candidates possibly 
mediating HDACi induced decay of endogenously overexpressed ERBB2 transcripts in breast 
cancer. hnRNP K demonstrated the most promising results in that its binding was significantly 
altered after 2-hour TSA treatment in comparison to the control (Fig. 17 and 18). Previous 
studies have illustrated that hnRNP K can be methylated at arginine residues, which plays a key 
role in coordinating transcriptional responses to DNA damage as a cofactor for p53 (Chen et al., 
2008). Upon DNA damage, hnRNP K is shielded from MDM2-mediated proteasomal 
degradation and then cooperates with p53 in transcriptional activation of cell-cycle arrest genes 
(Moumen et al., 2005). Additionally, hnRNP K can be modified by both acetylation and 
phosphorylation, strengthening the argument that HDACi treatment potentially induces hnRNP 
K acetylation as part of the ERBB2 transcript decay mechanism (Enge et al., 2009). However, 
further analysis of acetylation patterns of hnRNP K needs to be investigated.  
With the amount of hnRNPs that were identified by mass spectrometry, it is likely that 
hnRNPs form a complex, initiated by hnRNP K binding, to mediate ERBB2 mRNA decay. 
hnRNPs are complexes of RNA and protein present in the cell nucleus during gene transcription 
and subsequent post-transcriptional modification of mRNA (Han et al., 2013). They are known 
to bind RNA polymerase II transcripts to form hnRNP particles, and these play functional roles 
in DNA repair, telomere biogenesis, cell signaling, and gene expression regulation (Han et al., 
2013). The role of hnRNPs in mRNA stability and oncogene splicing are particular functions of 
interest. Each hnRNP protein contains at least one RNA-binding motif and the adenylate plus the 
uridylate-rich element (ARE) (Carpenter et al. 2006). They are commonly found in the 3' 
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untranslated region (UTR) of mRNAs and mediate the degradation of cytokine and proto-
oncogene mRNAs (Carpenter et al. 2006). In our case, these findings suggest that with the 
abundance of hnRNPs present in our mass spectrometry analysis, several of these proteins may 
form a complex and cooperate in mediating ERBB2 transcript decay. hnRNP K itself has been 
shown to be part of several complexes that bind to the ERBB2 promoter, regulate metastasis at 
the translational level, and promote tumorigenicity (Gumireddy et al., 2013; Sugimasa et al., 
2015; Zhang et al., 2012).  
Nonetheless, when taking into account the abundance of data generated through mass 
spectrometry, initial reports of sense-strand specific protein binding by mass spectrometry in 
many cases, such as PPIA and RNH1, could not be confirmed by Western blot analysis. The 
quality of the sample is the primary determinant for success in native mass spectrometry, and 
sample heterogeneity due to partial protein degradation or the binding of adducts can severely 
restrict the outcome of this technique (Van Duijn, 2010). Nonetheless, the use of mass 
spectrometry in the future can also allow us to identify acetylation patterns of protein in addition 
to their strand specificity. Another source of discrepancy for the Western blot results could 
include the epitope specificity of antibodies used to detect the specific protein during Western 
blot analysis coupled with the basic assumption that an exogenously supplied ERBB2 mRNA 
construct can function similarly to an endogenously produced ERBB2 transcript. Additionally, 
the in vitro results obtained in Figures 10-15 need to be verified by in vivo experiments to 
confirm their reproducibility and significance as well as to evaluate the utility of a ERBB2 
mRNA construct used in this study. 
In order to translate the present findings into some therapeutic value in treating ERBB2-
positive breast cancers, further experiments will need to be conducted using an HDAC inhibitor 
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that can be tested clinically instead of prototype tools, like TSA which is commonly used 
experimentally due to its commercial availability but lacks good bioavailability so cannot be 
used clinically. Currently, Panobinostat, developed by Novartis, is a pan-HDACi with the highest 
inhibitory potency among clinically used hydroxamic acids, and clinical trials are looking at its 
effectiveness in combination with transtuzumab to treat HER2-positive breast cancer (Dent et al., 
2009). In one study, patients who received 10 mg of Panobinostat three times weekly or 15 mg 
of Panobinostat on days 1 and 8 of a 21-day cycle in combination with weekly Trastuzumab have 
responded well to the treatment, and two of the patients have even shown a reduction in tumor 
size (Conte et al., 2009). A structurally similar compound, Dacinostat, inhibits HDACs in 
submicromolar concentrations and has demonstrated the ability to inhibit cell growth in addition 
to inducing apoptosis (Dent et al., 2009). Also known as LAQ824, it has been shown to down-
regulate HER2 by depleting HER2 transcripts and promoted its degradation by the proteasome 
(Fuino et al., 2003). Investigating the effects of these agents in place of TSA will help verify the 
mechanism of HDACi induced ERBB2 decay in breast cancer patients.  
Furthermore, development of transcript-targeted treatments coupled with small molecule 
and receptor-disabling agents could lead to a highly successful strategy for overcoming 
resistance to currently available receptor-targeted agents. Dacinostat was also shown to sensitize 
human breast cancer cells to transtuzumab and other receptor disabling agents (Fuino et al., 
2003). Another study focused on the combination of Vorinostat, a pan-HDACi, and Tamoxifen 
in breast cancer patients who progressed regardless of prior hormone therapy (Munster et al., 
2009). Hormone receptor signaling was disrupted with HDACi treatment, giving reason that 
resistance to hormone receptor modulators is reversible (Dent et al., 2009). Studies have shown 
that HDACi sensitizes ER-negative cell lines to Tamoxifen by inducing the release of HDAC1 
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from the ERα-promoter, and in turn, restoring expression of ERα (Yang et al., 2001; Zhou et al., 
2007) or by activation of ERβ (Hodges-Gallagher et al., 2006), involving an upregulation or 
translocation of ERβ (Duong et al., 2006; Jang et al., 2004). Six patients in this phase II study 
responded well to the treatment with no resistance to the combination for longer than 6 months, 
suggesting that this drug combination may help restore hormone sensitivity (Munster et al., 
2009). Progress in this effort could potentially lead to a cancer treatment strategy that is more 
effective and selective, and less toxic, than the use of currently available pan-HDACi for the 
treatment of ERBB2-overexpressing malignancies. Ultimately, advances in this research will 
greatly improve the survival likelihood of patients suffering from ERBB2-positive breast cancer. 
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 APPENDIX 1 
List of 42 protein candidates that displayed a 2 fold or greater binding to the sense strand over the antisense strand.
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APPENDIX 2 
Complete list of protein binding to the 3’UTR of ERBB2 discovered during mass spectrometry. 
 
Protein Gene 
10 kDa heat shock protein, mitochondrial  HSPE1 
14-3-3 protein epsilon YWHAE 
2,4-dienoyl-CoA reductase, mitochondrial DECR1 
26S proteasome non-ATPase regulatory subunit 11 PSMD11 
26S proteasome non-ATPase regulatory subunit 13 PSMD13 
26S proteasome non-ATPase regulatory subunit 3  PSMD3 
28S ribosomal protein S16, mitochondrial  MRPS16 
28S ribosomal protein S18b, mitochondrial MRPS18B 
28S ribosomal protein S22, mitochondrial MRPS22 
28S ribosomal protein S26, mitochondrial  MRPS26 
28S ribosomal protein S27, mitochondrial MRPS27 
28S ribosomal protein S29, mitochondrial DAP3 
28S ribosomal protein S5, mitochondrial MRPS5 
28S ribosomal protein S6, mitochondrial  MRPS6 
3-ketoacyl-CoA thiolase, mitochondrial ACAA2 
3-ketoacyl-CoA thiolase, peroxisomal ACAA1 
4-trimethylaminobutyraldehyde dehydrogenase  ALDH9A1 
40S ribosomal protein S10  RPS10 
40S ribosomal protein S11  RPS11 
40S ribosomal protein S14  RPS14 
40S ribosomal protein S15a RPS15A 
40S ribosomal protein S16  RPS16 
40S ribosomal protein S18  RPS18 
40S ribosomal protein S19  RPS19 
40S ribosomal protein S2 RPS2 
40S ribosomal protein S20  RPS20 
40S ribosomal protein S21  RPS21 
40S ribosomal protein S25  RPS25 
40S ribosomal protein S28  RPS28 
40S ribosomal protein S3 RPS3 
40S ribosomal protein S3a RPS3A 
40S ribosomal protein S4, X isoform RPS4X 
40S ribosomal protein S6 RPS6 
40S ribosomal protein S7  RPS7 
40S ribosomal protein S9  RPS9 
40S ribosomal protein SA RPSA 
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4F2 cell-surface antigen heavy chain  SLC3A2 
6-phosphofructokinase type C  PFKP 
6-phosphofructokinase, liver type  PFKL 
6-phosphogluconate dehydrogenase, decarboxylating PGD 
60 kDa heat shock protein, mitochondrial  HSPD1 
60S acidic ribosomal protein P0 RPLP0 
60S acidic ribosomal protein P0-like RPLP0P6 
60S acidic ribosomal protein P2  RPLP2 
60S ribosomal protein L11  RPL11 
60S ribosomal protein L12 RPL12 
60S ribosomal protein L17  RPL17 
60S ribosomal protein L18a  RPL18A 
60S ribosomal protein L22  RPL22 
60S ribosomal protein L24  RPL24 
60S ribosomal protein L26-like 1  RPL26L1 
60S ribosomal protein L27  RPL27 
60S ribosomal protein L27a  RPL27A 
60S ribosomal protein L28  RPL28 
60S ribosomal protein L3 RPL3 
60S ribosomal protein L30 RPL30 
60S ribosomal protein L31  RPL31 
60S ribosomal protein L34  RPL34 
60S ribosomal protein L35 RPL35 
60S ribosomal protein L38  RPL38 
60S ribosomal protein L4 RPL4 
60S ribosomal protein L5 RPL5 
60S ribosomal protein L6 RPL6 
60S ribosomal protein L7 RPL7 
60S ribosomal protein L7a RPL7A 
60S ribosomal protein L8 RPL8 
60S ribosomal protein L9  RPL9 
78 kDa glucose-regulated protein  HSPA5 
Acetyl-CoA acetyltransferase, mitochondrial ACAT1 
Acidic leucine-rich nuclear phosphoprotein 32 family member A ANP32A 
Acidic leucine-rich nuclear phosphoprotein 32 family member B ANP32B 
Acidic leucine-rich nuclear phosphoprotein 32 family member C ANP32C 
Acidic leucine-rich nuclear phosphoprotein 32 family member D ANP32D 
Aconitate hydratase, mitochondrial  ACO2 
Actin-related protein 2/3 complex subunit 4  ARPC4 
Actin-related protein 3 ACTR3 
Actin-related protein 3B ACTR3B 
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Actin, alpha skeletal muscle  ACTA1 
Actin, cytoplasmic 1 ACTB 
Actin, cytoplasmic 2 ACTG1 
Activated RNA polymerase II transcriptional coactivator p15 SUB1 
Acyl-coenzyme A thioesterase 13 ACOT13 
Acylamino-acid-releasing enzyme  APEH 
Adenosine kinase ADK 
Adenosylhomocysteinase AHCY 
ADP-ribosylation factor 1  ARF1 
ADP-ribosylation factor 4  ARF4 
ADP-ribosylation factor-like protein 8B  ARL8B 
ADP/ATP translocase 1 SLC25A4 
ADP/ATP translocase 2 SLC25A5 
ADP/ATP translocase 3 SLC25A6 
ADP/ATP translocase 4 SLC25A31 
Alanine--tRNA ligase, cytoplasmic  AARS 
Alcohol dehydrogenase [NADP(+)] AKR1A1 
Aldehyde dehydrogenase, mitochondrial  ALDH2 
Alpha-2-HS-glycoprotein AHSG 
Alpha-enolase  ENO1 
Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 AIMP1 
Annexin A11  ANXA11 
Annexin A2 ANXA2 
Annexin A5 ANXA5 
Annexin A6  ANXA6 
Annexin A7  ANXA7 
Anterior gradient protein 2 homolog  AGR2 
AP-1 complex subunit beta-1  AP1B1 
Apolipoprotein D  APOD 
Arginase-1  ARG1 
Arginine--tRNA ligase, cytoplasmic  RARS 
Argininosuccinate synthase ASS1 
Aspartate aminotransferase, cytoplasmic GOT1 
Aspartate aminotransferase, mitochondrial GOT2 
ATP synthase subunit alpha, mitochondrial  ATP5A1 
ATP synthase subunit beta, mitochondrial  ATP5B 
ATP-citrate synthase  ACLY 
ATP-dependent RNA helicase A  DHX9 
ATP-dependent RNA helicase DDX1 DDX1 
ATP-dependent RNA helicase DDX3X  DDX3X 
Basic leucine zipper and W2 domain-containing protein 2 BZW2 
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Bifunctional glutamate/proline--tRNA ligase  EPRS 
Biliverdin reductase A BLVRA 
C-1-tetrahydrofolate synthase, cytoplasmic MTHFD1 
CAD protein  CAD 
Calmodulin-like protein 5  CALML5 
Calnexin  CANX 
Calpain-2 catalytic subunit  CAPN2 
Calumenin CALU 
Carbamoyl-phosphate synthase [ammonia], mitochondrial  CPS1 
Carbonyl reductase [NADPH] 1 CBR1 
Caspase-14  CASP14 
Cathepsin D  CTSD 
Citrate synthase, mitochondrial CS 
Clathrin heavy chain 1  CLTC 
Clathrin light chain A CLTA 
Clathrin light chain B CLTB 
Coatomer subunit alpha  COPA 
Cofilin-1  CFL1 
Constitutive coactivator of PPAR-gamma-like protein 1  FAM120A 
Copine-3  CPNE3 
Creatine kinase B-type CKB 
Creatine kinase U-type, mitochondrial CKMT1A 
CTP synthase 1  CTPS1 
Cyclin-dependent kinase 1 CDK1 
Cyclin-dependent kinase 12 CDK12 
Cyclin-dependent kinase 13 CDK13 
Cyclin-dependent kinase 14 CDK14 
Cyclin-dependent kinase 15 CDK15 
Cyclin-dependent kinase 16 CDK16 
Cyclin-dependent kinase 17 CDK17 
Cyclin-dependent kinase 18 CDK18 
Cyclin-dependent kinase 2 CDK2 
Cyclin-dependent kinase 20 CDK20 
Cyclin-dependent kinase 3 CDK3 
Cyclin-dependent kinase 4 CDK4 
Cyclin-dependent kinase 5 CDK5 
Cyclin-dependent kinase 6 CDK6 
Cyclin-dependent kinase 9 CDK9 
Cytosolic non-specific dipeptidase  CNDP2 
D-3-phosphoglycerate dehydrogenase  PHGDH 
D-dopachrome decarboxylase DDT 
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Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial ECH1 
Dermcidin  DCD 
Desmoplakin  DSP 
Dihydrolipoyl dehydrogenase, mitochondrial  DLD 
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate 
dehydrogenase complex, mitochondrial  DLAT 
DNA-dependent protein kinase catalytic subunit PRKDC 
DNA-directed RNA polymerase II subunit RPB1  POLR2A 
DNA-directed RNA polymerase II subunit RPB2  POLR2B 
DNA-directed RNA polymerases I, II, and III subunit RPABC1  POLR2E 
DnaJ homolog subfamily C member 10  DNAJC10 
Dolichyl-diphosphooligosaccharide--protein glycosyltransferase 48 kDa 
subunit DDOST 
Dynamin-like 120 kDa protein, mitochondrial  OPA1 
E3 ubiquitin-protein ligase CHIP STUB1 
E3 ubiquitin-protein ligase TRIM21  TRIM21 
ELAV-like protein 1 ELAVL1 
Elongation factor 1-alpha 1 EEF1A1 
Elongation factor 1-alpha 2 EEF1A2 
Elongation factor 1-delta EEF1D 
Elongation factor 1-gamma  EEF1G 
Elongation factor 2  EEF2 
Elongation factor Tu, mitochondrial TUFM 
Endoplasmic reticulum resident protein 44 ERP44 
Endoplasmic reticulum-Golgi intermediate compartment protein 1 ERGIC1 
Endoplasmin  HSP90B1 
Epoxide hydrolase 1 EPHX1 
Eukaryotic initiation factor 4A-I EIF4A1 
Eukaryotic initiation factor 4A-III EIF4A3 
Eukaryotic peptide chain release factor subunit 1  ETF1 
Eukaryotic translation initiation factor 2 subunit 1 EIF2S1 
Eukaryotic translation initiation factor 2 subunit 2 EIF2S2 
Eukaryotic translation initiation factor 3 subunit A  EIF3A 
Eukaryotic translation initiation factor 3 subunit C  EIF3C 
Eukaryotic translation initiation factor 3 subunit E EIF3E 
Eukaryotic translation initiation factor 3 subunit F EIF3F 
Eukaryotic translation initiation factor 3 subunit I EIF3I 
Eukaryotic translation initiation factor 3 subunit J EIF3J 
Eukaryotic translation initiation factor 3 subunit L  EIF3L 
Eukaryotic translation initiation factor 4 gamma 1  EIF4G1 
Exportin-2  CSE1L 
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Ezrin  EZR 
F-actin-capping protein subunit alpha-1 CAPZA1 
F-actin-capping protein subunit alpha-2 CAPZA2 
Far upstream element-binding protein 1  FUBP1 
Far upstream element-binding protein 2  KHSRP 
Farnesyl pyrophosphate synthase FDPS 
Fatty acid synthase  FASN 
Fibroblast growth factor receptor 1 FGFR1 
Fibroblast growth factor receptor 2 FGFR2 
Fibroblast growth factor receptor 3 FGFR3 
Fibroblast growth factor receptor 4 FGFR4 
Fructose-bisphosphate aldolase A ALDOA 
Fumarate hydratase, mitochondrial  FH 
Fumarylacetoacetase FAH 
Galectin-3-binding protein LGALS3BP 
Galectin-7  LGALS7 
Gamma-glutamylcyclotransferase  GGCT 
Gasdermin-A  GSDMA 
Geranylgeranyl transferase type-2 subunit beta RABGGTB 
Glucose-6-phosphate 1-dehydrogenase  G6PD 
Glucose-6-phosphate 1-dehydrogenase  G6PD 
Glucose-6-phosphate isomerase GPI 
Glutamine synthetase GLUL 
Glutamine--fructose-6-phosphate aminotransferase [isomerizing] 1  GFPT1 
Glutamine--tRNA ligase  QARS 
Glutathione synthetase  GSS 
Glyceraldehyde-3-phosphate dehydrogenase GAPDH 
Glycine--tRNA ligase  GARS 
Glycogen debranching enzyme  AGL 
Glycogen phosphorylase, brain form  PYGB 
Glyoxylate reductase/hydroxypyruvate reductase GRHPR 
GTP-binding protein SAR1b  SAR1B 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 GNB1 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 GNB2 
Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 GNB3 
Guanine nucleotide-binding protein subunit beta-2-like 1 GNB2L1 
Guanine nucleotide-binding protein subunit beta-4 GNB4 
Heat shock 70 kDa protein 1A/1B HSPA1A 
Heat shock cognate 71 kDa protein  HSPA8 
Heat shock protein 105 kDa  HSPH1 
Heat shock protein 75 kDa, mitochondrial  TRAP1 
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Heat shock protein HSP 90-alpha  HSP90AA1 
Heat shock protein HSP 90-beta HSP90AB1 
Heterogeneous nuclear ribonucleoprotein A/B HNRNPAB 
Heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 
Heterogeneous nuclear ribonucleoprotein A1-like 2 HNRNPA1L2 
Heterogeneous nuclear ribonucleoprotein A3 HNRNPA3 
Heterogeneous nuclear ribonucleoprotein C-like 1 HNRNPCL1 
Heterogeneous nuclear ribonucleoprotein D-like HNRNPDL 
Heterogeneous nuclear ribonucleoprotein D0 HNRNPD 
Heterogeneous nuclear ribonucleoprotein F  HNRNPF 
Heterogeneous nuclear ribonucleoprotein H HNRNPH1 
Heterogeneous nuclear ribonucleoprotein H3 HNRNPH3 
Heterogeneous nuclear ribonucleoprotein K  HNRNPK 
Heterogeneous nuclear ribonucleoprotein L  HNRNPL 
Heterogeneous nuclear ribonucleoprotein M  HNRNPM 
Heterogeneous nuclear ribonucleoprotein Q  SYNCRIP 
Heterogeneous nuclear ribonucleoprotein R  HNRNPR 
Heterogeneous nuclear ribonucleoprotein U  HNRNPU 
Heterogeneous nuclear ribonucleoprotein U-like protein 1  HNRNPUL1 
Heterogeneous nuclear ribonucleoprotein U-like protein 2  HNRNPUL2 
Heterogeneous nuclear ribonucleoproteins A2/B1 HNRNPA2B1 
Heterogeneous nuclear ribonucleoproteins C1/C2 HNRNPC 
Hexokinase-1  HK1 
Histidine--tRNA ligase, cytoplasmic  HARS 
Histone-arginine methyltransferase CARM1  CARM1 
Hypoxia up-regulated protein 1  HYOU1 
Ig gamma-1 chain C region IGHG1 
Ig gamma-3 chain C region IGHG3 
Immunoglobulin lambda-like polypeptide 5  IGLL5 
Importin subunit beta-1  KPNB1 
Inorganic pyrophosphatase PPA1 
Inorganic pyrophosphatase 2, mitochondrial PPA2 
Inosine-5'-monophosphate dehydrogenase 1  IMPDH1 
Inosine-5'-monophosphate dehydrogenase 1  IMPDH1 
Inosine-5'-monophosphate dehydrogenase 2  IMPDH2 
Interleukin enhancer-binding factor 2 ILF2 
Interleukin enhancer-binding factor 3  ILF3 
Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial IDH3A 
Isocitrate dehydrogenase [NADP] cytoplasmic IDH1 
Isocitrate dehydrogenase [NADP], mitochondrial IDH2 
Isoleucine--tRNA ligase, cytoplasmic  IARS 
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Keratinocyte proline-rich protein  KPRP 
L-lactate dehydrogenase A chain LDHA 
L-lactate dehydrogenase B chain LDHB 
La-related protein 1  LARP1 
Lamin-B2  LMNB2 
LanC-like protein 1 LANCL1 
Leucine--tRNA ligase, cytoplasmic  LARS 
Lupus La protein  SSB 
Lysine--tRNA ligase  KARS 
Lysosome-associated membrane glycoprotein 1  LAMP1 
Malate dehydrogenase, cytoplasmic MDH1 
Malate dehydrogenase, mitochondrial MDH2 
Methionine--tRNA ligase, cytoplasmic  MARS 
mRNA cap guanine-N7 methyltransferase  RNMT 
Mucin-like protein 1  MUCL1 
Multifunctional protein ADE2 PAICS 
Myosin light polypeptide 6  MYL6 
Myosin regulatory light polypeptide 9  MYL9 
Myosin-9  MYH9 
N-terminal kinase-like protein  SCYL1 
NAD(P)H dehydrogenase [quinone] 1 NQO1 
NADP-dependent malic enzyme  ME1 
Nascent polypeptide-associated complex subunit alpha NACA 
Neuroblast differentiation-associated protein AHNAK  AHNAK 
Neutral alpha-glucosidase AB  GANAB 
Nicotinate phosphoribosyltransferase  NAPRT1 
Nitric oxide-associated protein 1  NOA1 
Non-POU domain-containing octamer-binding protein  NONO 
Nuclear migration protein nudC NUDC 
Nuclear protein localization protein 4 homolog  NPLOC4 
Nuclease-sensitive element-binding protein 1 YBX1 
Nucleolin  NCL 
Nucleolysin TIA-1 isoform p40 TIA1 
Nucleolysin TIAR TIAL1 
Nucleophosmin NPM1 
Nucleoside diphosphate kinase A  NME1 
Obg-like ATPase 1 OLA1 
Ornithine aminotransferase, mitochondrial OAT 
Peflin PEF1 
Peptidyl-prolyl cis-trans isomerase A  PPIA 
Peptidyl-prolyl cis-trans isomerase B  PPIB 
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Peptidyl-prolyl cis-trans isomerase FKBP4 FKBP4 
Peroxiredoxin-1  PRDX1 
Peroxiredoxin-2  PRDX2 
Peroxiredoxin-5, mitochondrial  PRDX5 
Peroxisomal acyl-coenzyme A oxidase 1  ACOX1 
Phenylalanine--tRNA ligase alpha subunit  FARSA 
Phenylalanine--tRNA ligase beta subunit  FARSB 
Phosphatidylethanolamine-binding protein 1  PEBP1 
Phosphoglucomutase-1  PGM1 
Phosphoglycerate kinase 1 PGK1 
Phosphoserine aminotransferase PSAT1 
Plasminogen activator inhibitor 1 RNA-binding protein  SERBP1 
Plastin-2  LCP1 
Plastin-3  PLS3 
Poly [ADP-ribose] polymerase 1  PARP1 
Poly(rC)-binding protein 1 PCBP1 
Polyadenylate-binding protein 1 PABPC1 
Polyadenylate-binding protein 1-like PABPC1L 
Polyadenylate-binding protein 4  PABPC4 
Polyadenylate-binding protein 5 PABPC5 
Polypyrimidine tract-binding protein 1  PTBP1 
POTE ankyrin domain family member E  POTEE 
Pre-mRNA-processing factor 39  PRPF39 
Prelamin-A/C LMNA 
Probable ATP-dependent RNA helicase DDX17  DDX17 
Probable ATP-dependent RNA helicase DDX5  DDX5 
Profilin-1 PFN1 
Programmed cell death 6-interacting protein  PDCD6IP 
Programmed cell death protein 6  PDCD6 
Proliferating cell nuclear antigen PCNA 
Proliferation-associated protein 2G4 PA2G4 
Proliferation-associated protein 2G4  PA2G4 
Proteasome subunit beta type-1  PSMB1 
Proteasome subunit beta type-2  PSMB2 
Proteasome subunit beta type-4  PSMB4 
Proteasome subunit beta type-6  PSMB6 
Protein arginine N-methyltransferase 1 PRMT1 
Protein diaphanous homolog 1  DIAPH1 
Protein disulfide-isomerase P4HB 
Protein disulfide-isomerase A3  PDIA3 
Protein disulfide-isomerase A4  PDIA4 
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Protein disulfide-isomerase A6  PDIA6 
Protein DJ-1  PARK7 
Protein kinase C and casein kinase substrate in neurons protein 2  PACSIN2 
Protein S100-A6  S100A6 
Protein S100-A8 S100A8 
Protein S100-A9  S100A9 
Protein SEC13 homolog SEC13 
Protein SET SET 
Protein SETSIP SETSIP 
Protein Shroom3  SHROOM3 
Protein TFG TFG 
Protein transport protein Sec16A  SEC16A 
Protein transport protein Sec23B  SEC23B 
Protein transport protein Sec24A  SEC24A 
Protein transport protein Sec24B SEC24B 
Protein transport protein Sec24C  SEC24C 
Protein transport protein Sec24D  SEC24D 
Protein transport protein Sec31A  SEC31A 
Prothymosin alpha PTMA 
Purine nucleoside phosphorylase PNP 
Putative 40S ribosomal protein S26-like 1  RPS26P11 
Putative annexin A2-like protein ANXA2P2 
Putative ATP-dependent RNA helicase DHX30  DHX30 
Putative elongation factor 1-alpha-like 3 EEF1A1P5 
Putative elongation factor 1-alpha-like 3  EEF1A1P5 
Putative heat shock protein HSP 90-beta 2  HSP90AB2P 
Putative protein FAM10A4  ST13P4 
Putative protein FAM10A5  ST13P5 
Putative synaptogyrin-2 like protein  None 
Pyrroline-5-carboxylate reductase 1, mitochondrial PYCR1 
Pyrroline-5-carboxylate reductase 2 PYCR2 
Pyruvate dehydrogenase E1 component subunit alpha, somatic form, 
mitochondrial PDHA1 
Pyruvate kinase PKLR PKLR 
Pyruvate kinase PKLR PKLR 
Pyruvate kinase PKM PKM 
Rab GDP dissociation inhibitor beta  GDI2 
Ras GTPase-activating-like protein IQGAP1  IQGAP1 
Ras-related protein Rab-1B  RAB1B 
Ras-related protein Rab-7a  RAB7A 
Receptor tyrosine-protein kinase erbB-2  ERBB2 
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Replication protein A 14 kDa subunit RPA3 
Replication protein A 32 kDa subunit RPA2 
Replication protein A 70 kDa DNA-binding subunit  RPA1 
Replication protein A 70 kDa DNA-binding subunit  RPA1 
Reticulon-4 RTN4 
Ribonuclease inhibitor RNH1 
Ribose-phosphate pyrophosphokinase 1 PRPS1 
Ribose-phosphate pyrophosphokinase 2 PRPS2 
RNA-binding protein EWS  EWSR1 
RNA-binding protein FUS  FUS 
RuvB-like 1  RUVBL1 
Serine hydroxymethyltransferase, mitochondrial  SHMT2 
Serine/threonine-protein kinase ICK ICK 
Serine/threonine-protein kinase MAK MAK 
Serpin B4  SERPINB4 
Serum albumin  ALB 
Single-stranded DNA-binding protein, mitochondrial SSBP1 
Small nuclear ribonucleoprotein E SNRPE 
Small nuclear ribonucleoprotein Sm D2  SNRPD2 
Sodium/potassium-transporting ATPase subunit alpha-1  ATP1A1 
Sorcin  SRI 
Sorting nexin-9  SNX9 
Spermidine synthase SRM 
Spliceosome RNA helicase DDX39B  DDX39B 
Squamous cell carcinoma antigen recognized by T-cells 3  SART3 
Src substrate cortactin  CTTN 
Staphylococcal nuclease domain-containing protein 1  SND1 
Stress-70 protein, mitochondrial  HSPA9 
Stress-induced-phosphoprotein 1  STIP1 
Succinyl-CoA ligase [GDP-forming] subunit beta, mitochondrial SUCLG2 
Superoxide dismutase [Cu-Zn]  SOD1 
Synaptogyrin-2 SYNGR2 
T-complex protein 1 subunit alpha  TCP1 
T-complex protein 1 subunit beta  CCT2 
T-complex protein 1 subunit delta  CCT4 
T-complex protein 1 subunit epsilon  CCT5 
T-complex protein 1 subunit eta  CCT7 
T-complex protein 1 subunit gamma  CCT3 
T-complex protein 1 subunit theta CCT8 
T-complex protein 1 subunit zeta  CCT6A 
Tax1-binding protein 1  TAX1BP1 
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Thioredoxin  TXN 
Thioredoxin domain-containing protein 5 TXNDC5 
Thioredoxin-dependent peroxide reductase, mitochondrial  PRDX3 
Thiosulfate sulfurtransferase/rhodanese-like domain-containing protein 1 TSTD1 
Threonine--tRNA ligase, cytoplasmic  TARS 
Thymidine phosphorylase  TYMP 
Transaldolase TALDO1 
Transcription activator BRG1  SMARCA4 
Transcription elongation factor SPT5  SUPT5H 
Transcriptional activator protein Pur-alpha PURA 
Transcriptional activator protein Pur-beta PURB 
Transcriptional adapter 2-beta  TADA2B 
Transcriptional adapter 2-beta  TADA2B 
Transferrin receptor protein 1  TFRC 
Transgelin-2  TAGLN2 
Transitional endoplasmic reticulum ATPase  VCP 
Transketolase TKT 
Trifunctional enzyme subunit alpha, mitochondrial  HADHA 
Tripartite motif-containing protein 3  TRIM3 
tRNA (cytosine(34)-C(5))-methyltransferase  NSUN2 
tRNA selenocysteine 1-associated protein 1 TRNAU1AP 
tRNA-splicing ligase RtcB homolog  RTCB 
Tubulin alpha-1A chain TUBA1A 
Tubulin alpha-1B chain TUBA1B 
Tubulin alpha-1C chain TUBA1C 
Tubulin alpha-3E chain TUBA3E 
Tubulin beta chain TUBB 
Tubulin beta-1 chain TUBB1 
Tubulin beta-2A chain TUBB2A 
Tubulin beta-2B chain TUBB2B 
Tubulin beta-3 chain TUBB3 
Tubulin beta-4A chain TUBB4A 
Tubulin beta-4B chain TUBB4B 
Tubulin beta-6 chain TUBB6 
Tubulin beta-8 chain TUBB8 
Tubulin-specific chaperone A  TBCA 
Tyrosine-protein kinase Blk BLK 
Tyrosine-protein kinase Fgr FGR 
Tyrosine-protein kinase Fyn FYN 
Tyrosine-protein kinase HCK HCK 
Tyrosine-protein kinase Lck LCK 
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Tyrosine-protein kinase Lyn LYN 
Tyrosine-protein kinase Yes YES1 
U1 small nuclear ribonucleoprotein A SNRPA 
Ubiquitin carboxyl-terminal hydrolase 13  USP13 
Ubiquitin-like modifier-activating enzyme 1  UBA1 
UDP-glucose:glycoprotein glucosyltransferase 1  UGGT1 
UTP--glucose-1-phosphate uridylyltransferase  UGP2 
Vacuolar protein sorting-associated protein 35  VPS35 
Valine--tRNA ligase  VARS 
Very long-chain specific acyl-CoA dehydrogenase, mitochondrial  ACADVL 
Vesicle-trafficking protein SEC22b  SEC22B 
Vinculin VCL 
WD repeat-containing protein 1  WDR1 
WD repeat-containing protein 61 WDR61 
X-ray repair cross-complementing protein 5  XRCC5 
X-ray repair cross-complementing protein 6  XRCC6 
YTH domain-containing family protein 2  YTHDF2 
Zinc-alpha-2-glycoprotein  AZGP1 
 
